TY - JOUR
T1 - Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease
T2 - A nested case-control study
AU - Bouwmans, Pim
AU - Malahe, S Reshwan K
AU - Messchendorp, A Lianne
AU - RECOVAC Consortium / RECOVAC Collaborators
AU - Vart, Priya
AU - Imhof, Céline
AU - Sanders, Jan-Stephan F
AU - Gansevoort, Ron T
AU - de Vries, Aiko P J
AU - Abrahams, Alferso C
AU - Bemelman, Frederike J
AU - Vervoort, Johanna P M
AU - Hilbrands, Luuk B
AU - Ten Dam, Marc A G J
AU - van den Dorpel, René M A
AU - Rispens, Theo
AU - Steenhuis, Maurice
AU - Reinders, Marlies E J
AU - Hemmelder, Marc H
N1 - Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2024/5
Y1 - 2024/5
N2 - Background: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease. Methods: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4–G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition. Results: Two hundred sixteen CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17–1.78)], P < 0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per 10-fold increase in antibody level after vaccination (aOR 0.82 [0.70–0.96], P = 0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61–8.25], P = 0.003). Conclusions: CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19.
AB - Background: The burden of post COVID-19 condition (PCC) is not well studied in patients with advanced kidney disease. Methods: A large prospective cohort of SARS-CoV-2 vaccinated patients with chronic kidney disease stages G4–G5 (CKD G4/5), on dialysis, and kidney transplant recipients (KTR) were included. Antibody levels were determined after vaccination. Presence of long-lasting symptoms was assessed in patients with and without prior COVID-19 and compared using logistic regression. In patients with prior COVID-19, PCC was defined according to the WHO definition. Results: Two hundred sixteen CKD G4/5 patients, 375 dialysis patients, and 2005 KTR were included. Long-lasting symptoms were reported in 204/853 (24%) patients with prior COVID-19 and in 297/1743 (17%) patients without prior COVID-19 (aOR: 1.45 (1.17–1.78)], P < 0.001). PCC was prevalent in 29% of CKD G4/5 patients, 21% of dialysis patients, and 24% of KTR. In addition, 69% of patients with PCC reported (very) high symptom burden. Odds of PCC was lower per 10-fold increase in antibody level after vaccination (aOR 0.82 [0.70–0.96], P = 0.01) and higher in case of COVID-19 related hospital admission (aOR 4.64 [2.61–8.25], P = 0.003). Conclusions: CKD G4/5 patients, dialysis patients, and KTR are at risk for PCC with high symptom burden after SARS-CoV-2 vaccination, especially if antibody levels are low and in case of hospitalization due to COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85188935763&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2024.106990
DO - 10.1016/j.ijid.2024.106990
M3 - Article
C2 - 38428480
SN - 1201-9712
VL - 142
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
M1 - 106990
ER -
